Background
We examined whether primary prevention with statins and high adherence to statins reduce the associated risk of cardiovascular events or death in a low‐risk population with type 2 diabetes mellitus (T2D).
Methods and Results
Using Danish nationwide registers, we included patients with new‐onset T2D, aged 40 to 89 years, between 2005 and 2011, who were alive 18 months following the T2D diagnosis (index date). In patients who purchased statins within 6 months following T2D diagnosis, we calculated the proportion of days covered (PDC) within 1 year after the initial 6‐month period. We studied the combined end point of myocardial infarction, stroke, or all‐cause mortality, whichever came first, with Cox regression. Reported were standardized 5‐year risk differences for fixed comorbidity distribution according to statin treatment history, stratified by sex and age. Among 77 170 patients, 42 975 (56%) were treated with statins, of whom 31 061 (72%) had a PDC ≥80%. In men aged 70 to 79 years who were treated with statins, the standardized 5‐year risk was 22.9% (95% CI, 21.5%–24.3%), whereas the risk was 29.1% (95% CI, 27.4%–30.7%) in men not treated, resulting in a significant risk reduction of 6.2% (95% CI, 4.0%–8.4%),
P
<0.0001. The risk reduction associated with statins increased with advancing age group (women: age 40–49 years, 0.0% [95% CI, −1.0% to 1.0%]; age 80–89 years, 10.8% [95% CI, 7.2%–14.4%]). Standardizing to all patients treated with statins, PDC <80% was associated with increased risk difference (reference PDC ≥80%; PDC <20%, 4.2% [95% CI, 2.9%–5.6%]).
Conclusions
This study supports the use of statins as primary prevention against cardiovascular diseases or death in 18‐month surviving low‐risk patients with T2D, with the highest effect in the elderly and adherent patients.
Decreased serum growth differentiation factor 15 levels after lifestyle intervention in patients with newly diagnosed type 2 diabetes mellitus